Brief: Eylea HD Approved By FDA As First And Only Injectable Anti-Vegf With Dosing Intervals Up To 5 Months
02/04/2026 17:36
April 2 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: EYLEA HD® (AFLIBERCEPT) APPROVED BY FDA AS FIRST AND ONLY INJECTABLE ANTI-VEGF WITH DOSING INTERVALS UP TO 5 MONTHS FOR WET AGE-RELATED MACULAR DEGENERATION (WAMD) AND DIABETIC MACULAR EDEMA (DME) REGENERON PHARMACEUTICALS INC - FDA TARGET ACTION DATE IN APRIL 2026 FOR EYLEA HD PREFILLED SYRINGE Source text: ID:nGNX7ty14s Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)